First case of cutaneous sarcoidosis within tattoos under durvalumab.

Immunotherapy is becoming one of today's most important systemic treatments in oncology after demonstrating its efficacy and acceptable tolerance in many types of cancer.[1] However, with increasing patient exposition, new side effects appear, including cutaneous ones. This granulomatous reaction, as triggers, could induce widespread reactions in other black tattoos, called a "rush phenomenon".[5] The granulomatous reactions related to immunotherapy, whether cutaneous or systemic, correspond to a real entity that is still poorly understood. 5 Sepehri M, Hutton Carlsen K, Serup J. Papulo-nodular reactions in black tattoos as markers of sarcoidosis: study of 92 tattoo reactions from a hospital material. [Extracted from the article]